Abstract 9947: Dual versus Single Antiplatelet Therapy with Clopidogrel in Spontaneous Coronary Artery Dissection: A Propensity-Matched Real-World Analysis
Abstract
Background: Spontaneous coronary artery dissection (SCAD) is a non-atherosclerotic cause of acute coronary syndrome predominantly affecting women, accounting for up to 35% of acute coronary syndromes in women under 50. Consensus statements favor single antiplatelet therapy (SAPT), but prior observational studies have compared dual antiplatelet therapy (DAPT) only against aspirin-based SAPT regimens. The direct comparison of DAPT with clopidogrel monotherapy in SCAD has not been reported. We hypothesized that DAPT would not be associated with improved cardiovascular outcomes compared with clopidogrel monotherapy in SCAD. Methods: Using the TriNetX US Collaborative Network (2015-2024), we identified adults with SCAD (ICD-10-CM I25.42), excluding iatrogenic dissection (I97.51). Patients initiated on DAPT (aspirin plus clopidogrel) or clopidogrel monotherapy within 7 days of diagnosis were 1:1 propensity score matched on demographics, comorbidities, medications, laboratory values, and healthcare utilization. Outcomes from day 7 to 365 included a composite of major adverse cardiovascular events (MACE; mortality, MI, or stroke), acute MI (AMI), percutaneous coronary intervention (PCI), recurrent SCAD, and all-cause mortality. Bleeding and stroke events were too infrequent at one year for reliable hazard ratio estimation in this cohort. Hazard ratios were calculated using Cox proportional hazards models, and E-values were computed for robustness to unmeasured confounding. Results: After matching, 504 patients per arm were available; women comprised 64% of the cohort. Compared with clopidogrel monotherapy, DAPT was associated with significantly higher rates of MACE (HR 1.45, 95% CI 1.17-1.79; E-value 2.25), AMI (HR 1.43, 95% CI 1.14-1.81; E-value 2.22), and all-cause mortality (HR 1.86, 95% CI 1.03-3.35; E-value 3.11). PCI (HR 1.62, 95% CI 0.95-2.76) and recurrent SCAD (HR 1.10, 95% CI 0.85-1.43) trended in the same direction. Conclusions: In this propensity-matched real-world analysis of patients with SCAD, DAPT was associated with higher rates of major adverse cardiovascular events and mortality compared with clopidogrel monotherapy, robust to substantial unmeasured confounding by E-value analysis. These findings, in a comparator not previously studied in SCAD, align with prior observational evidence and support ongoing equipoise for randomized trials of antiplatelet strategy in this disease.